Insider Selling: Calidi Biotherapeutics, Inc. (NYSE:CLDI) CEO Sells 10,000 Shares of Stock

Calidi Biotherapeutics, Inc. (NYSE:CLDI) CEO Allan Camaisa sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $1.62, for a total value of $16,200.00. Following the sale, the chief executive officer now directly owns 66,712 shares of the company’s stock, valued at $108,073.44. This represents a 13.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Calidi Biotherapeutics Stock Performance

Shares of NYSE:CLDI opened at $1.36 on Friday. The firm’s 50 day moving average is $1.69. Calidi Biotherapeutics, Inc. has a 12-month low of $0.73 and a 12-month high of $18.50.

Calidi Biotherapeutics (NYSE:CLDI) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.20. As a group, research analysts predict that Calidi Biotherapeutics, Inc. will post -4.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Calidi Biotherapeutics

A hedge fund recently raised its stake in Calidi Biotherapeutics stock. RS Crum Inc. raised its holdings in Calidi Biotherapeutics, Inc. (NYSE:CLDI) by 2,327.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 263,470 shares of the company’s stock after purchasing an additional 252,616 shares during the quarter. RS Crum Inc. owned 0.52% of Calidi Biotherapeutics worth $53,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 12.53% of the stock is owned by hedge funds and other institutional investors.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.